IP Library Granted Patent US 8,718,994
Granted Patent B2
US 8,718,994 · App. 12/936,434 · Granted May 6, 2014

Ligands for the GLP-1 receptor and methods for discovery thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,718,994
App. No.
12/936,434
Granted
May 6, 2014
Kind
B2
Abstract

Disclosed is the three-dimensional (3-D) structure of the GLP-1 receptor (GLP-1R) and methods by which the structure may be used to develop compounds that bind to, and/or modulate the GLP-1R. The technology described herein may be applied to the development of compounds that target the GLP-1R, or may be used to develop target compound that may bind to, and/or modulate the activity of the GLP-1R.

Claims (20)

1. A method for identifying a compound having the ability to modulate the GLP-1 receptor (GLP-1R), the method comprising the steps of:

generating a first three-dimensional model of the GLP-1R;

generating a second three-dimensional model of a potential modulator compound;

using a computer to dock the second three-dimensional model with the first three-dimensional model; and

quantifying at least one atomic interaction between the potential modulator compound and the GLP-1R, or a portion thereof,

wherein

the first three-dimensional model is a computer model of the GLP-1R, wherein the computer model comprises extracellular, transmembrane, and intracellular domains of GLP-1R;

the second three-dimensional model is a computer model of the potential modulator compound and the potential modulator compound has a molecular weight of less than 2,000 daltons;

the atomic interaction between the potential modulator compound and the GLP-1R does not interfere with the binding of native GLP-1 to the GLP-1R;

the atomic interaction between the potential modulator compound and the GLP-1R comprises at least one atomic interaction between the potential modulator compound and at least one of the amino acid residues selected from the group consisting of Ser31, Thr35, Trp39, Arg43, Thr65, Phe66, Glu68, Asp67, Tyr69, Trp91, Leu89, Tyr88, Arg121, Arg102, Leu123, Glu127, Trp110 and Glu128 of the GLP-1R; and

the atomic interaction between the potential modulator compound and the GLP-1R comprises at least one atomic interaction between the potential modulator compound and at least one of the amino acid residues selected from the group consisting of Arg376 and Arg380.

2. The method of claim 1 , further comprising:

modifying the computer model of the potential modulator compound; and

evaluating how modifying the computer model of the potential modulator compound changes at least one atomic interaction between the first three-dimensional model and the second three-dimensional model.

3. The method of claim 2 , wherein the step of modifying the computer model of the potential modulator compound comprises:

searching a library of molecular structures for molecular fragments that can be linked to the potential modulator compound, wherein a molecular fragment comprises at least one atom; and

linking a fragment to the potential modulator compound to generate a modified computer model of the compound.

4. The method of claim 1 , wherein the atomic interaction between a potential modulator compound and the GLP-1R, or a portion thereof, comprises at least one atomic interaction selected from the group consisting of charge, electrostatic, hydrogen bond and hydrophobic.

5. The method of claim 1 , wherein the atomic interaction between a potential modulator compound and the GLP-1R, or a portion thereof, comprises at least two hydrogen bond atomic interactions, at least two hydrophobic atomic interactions and at least one of a charge or electrostatic atomic interaction.

6. The method of claim 1 , wherein the atomic interaction between a potential modulator compound and the GLP-1R, or a portion thereof, comprises at least three hydrogen bond atomic interactions, at least three hydrophobic atomic interactions and at least one of a charge or electrostatic atomic interaction.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Jan 27, 2021
From: HORIZON TECHNOLOGY FINANCE CORPORATION, AS COLLATERAL AGENT
To: VTV THERAPEUTICS LLC
Reel/Frame 055133/0214 →
SECURITY INTEREST Recorded Apr 18, 2018
From: VTV THERAPEUTICS LLC
To: HORIZON TECHNOLOGY FINANCE CORPORATION, AS COLLATERAL AGENT
Reel/Frame 045969/0774 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 036254 FRAME: 0780. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 24, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS I LLC
Reel/Frame 036675/0407 →
RELEASE OF SECURITY INTEREST Recorded Aug 3, 2015
From: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
To: VTVX HOLDINGS II LLC
Reel/Frame 036254/0780 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: VTVX HOLDINGS I LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036242/0354 →
CHANGE OF NAME Recorded Jul 30, 2015
From: VTV THERAPEUTICS LLC
To: VTVX HOLDINGS I LLC
Reel/Frame 036236/0165 →
CHANGE OF NAME Recorded Jun 25, 2015
From: TRANSTECH PHARMA, LLC
To: VTV THERAPEUTICS LLC
Reel/Frame 036026/0219 →
SECURITY INTEREST Recorded Feb 26, 2015
From: TRANSTECH PHARMA, LLC
To: M&F TTP HOLDINGS LLC, AS COLLATERAL AGENT
Reel/Frame 035103/0356 →
NOTICE OF RELEASE OF SECURITY INTEREST IN PATENTS FOR REEL/FRAME 030982/0803 Recorded Apr 7, 2014
From: M&F TTP HOLDINGS LLC
To: TRANSTECH PHARMA, LLC
Reel/Frame 032621/0860 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 26, 2013
From: TRANSTECH PHARMA, INC.
To: TRANSTECH PHARMA, LLC
Reel/Frame 031678/0682 →
SECURITY AGREEMENT Recorded Aug 9, 2013
From: TRANSTECH PHARMA, INC.
To: M&F TTP HOLDINGS LLC C/O MACANDREWS & FORBES HOLDINGS INC.
Reel/Frame 030982/0803 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2010
From: RAO, MOHAN
To: TRANSTECH PHARMA, INC.
Reel/Frame 025091/0337 →